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Abstract
Background: DNA methylation aberration and microRNA (miRNA) deregulation have been observed in many types of
cancers. A systematic study of methylome and transcriptome in bladder urothelial carcinoma has never been reported.
Methodology/Principal Findings: The DNA methylation was profiled by modified methylation-specific digital karyotyping
(MMSDK) and the expression of mRNAs and miRNAs was analyzed by digital gene expression (DGE) sequencing in tumors
and matched normal adjacent tissues obtained from 9 bladder urothelial carcinoma patients. We found that a set of
significantly enriched pathways disrupted in bladder urothelial carcinoma primarily related to ‘‘neurogenesis’’ and ‘‘cell
differentiation’’ by integrated analysis of -omics data. Furthermore, we identified an intriguing collection of cancer-related
genes that were deregulated at the levels of DNA methylation and mRNA expression, and we validated several of these
genes (HIC1, SLIT2, RASAL1, and KRT17) by Bisulfite Sequencing PCR and Reverse Transcription qPCR in a panel of 33
bladder cancer samples.
Conclusions/Significance: We characterized the profiles between methylome and transcriptome in bladder urothelial
carcinoma, identified a set of significantly enriched key pathways, and screened four aberrantly methylated and expressed
genes. Conclusively, our findings shed light on a new avenue for basic bladder cancer research.
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Introduction
As genetic and epigenetic abnormalities have been observed in
the development of cancer cells [1], it has been theorized that they
both play important roles in oncogenesis, inducing changes in gene
activity and chromosome structure [2]. Basic research to reveal
mechanisms of carcinogenesis is extremely important for the
diagnosis, treatment and prognosis of cancers in the clinic. The
aberration of DNA methylation in cancer can occur as global
hypomethylation or locus-specific hypermethylation in CpG
island-rich promoters [3]. DNA hypomethylation in a cancer cell
is thought to lead to chromosome instability and oncogene
activation [4]. Conversely, aberrant promoter methylation or
hypermethylation of CpG islands-associated genes is strongly
associated with transcriptional silencing of these genes [5]. In
addition to DNA methylation, deregulated miRNAs in cancer may
affect the expression of genes and pathways that are involved in
cancer pathogenesis all the way from initiation to metastasis. Some
miRNAs serve as putative tumor suppressors and others act as
oncogenes [6].
Bladder cancer is one of the most common cancers in the world.
In 2008, an estimated 386,300 new cases were diagnosed, and
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carcinoma of the bladder, the most prevalent histological type of
bladder cancer, makes up more than 90% of the malignant cases
of the bladder cancer [8]. DNA hypomethylation is a common
phenomenon in bladder cancer [9,10]. Meanwhile, the relation-
ship between DNA methylation and bladder cancer has primarily
been studied with regard to promoter hypermethylation of tumor
suppressor genes. Inappropriate silencing of these genes by
promoter hypermethylation contributes to cancer initiation,
progression, invasion, and metastasis [11,12,13]. A number of
studies have examined both small and large panels of DNA
methylation events in bladder cancer using array-based technol-
ogies [9,10,14]. However, genome-wide detection studies to obtain
high-resolution methylation data in bladder cancer are rare. The
tumor-suppressor and oncogenic functions of miRNAs have been
observed in bladder cancer as well [15,16,17]. Several miRNA
profilings by microarrays in bladder cancer have also been carried
out, but no consistent conclusion could be always drawn from their
results [18,19,20].
Based on above observations, we hypothesized that a systematic
analysis on profiles of DNA methylation and expression of both
mRNA and microRNA in bladder cancer would help to identify
key alterations of bladder cancer. Thus, we carried out a genome-
wide methylation analysis in matched tumor and normal adjacent
tissues from 9 bladder urothelial carcinoma patients using
modified methylation-specific digital karyotyping (MMSDK),
combined with mRNA and miRNA expression data (coupled
with the results of our previous studies on mRNA [21] and
miRNA [22] of bladder cancer), which was obtained from tag
sequencing using second-generation sequencing technology.
Results
An overview of methylome and transcriptome in bladder
urothelial carcinoma
For DNA methylation, an average of 4,445,972 and 4,525,269
uniquely mapped tags that were 17 and 18 nt in length were
obtained from 9 different bladder urothelial carcinomas and their
matched normal adjacent tissues, respectively. For gene expres-
sion, the DGE libraries generated 3,307,536 and 3,136,370 high-
quality tags for tumor and normal tissues, respectively. In non-
coding small RNA (sRNAs) sequencing, a total of 14,787,388 and
12,754,928 high-quality reads were obtained for tumor and
normal tissues, respectively. In total, 16,236 genes and 543
miRNAs were detected expressed in at least one of the tumor or
normal adjacent tissue samples.
To obtain an overview of the differences in the DNA
methylation patterns with regard to the gene expression profiles
in the bladder urothelial carcinomas and their matched normal
adjacent tissues, the log2-transformed, average-fold changes
between tumor and normal tissues for the three types of tags
were plotted for the entire genome (Figure 1A). At a threshold of
|log2Ratio|$1, we observed some differences in the tags that
represent the methylation status at certain MluI genomic loci and
the mRNA expression level between cancer tissues and normal
controls, Furthermore, a global up-regulation of miRNAs in
bladder cancer was observed.
To further examine the methylation status at different genomic
regions, we compared the methylation profiles of promoters with
or without CpG islands (CGIs), exons and introns of bladder
urothelial carcinoma tissues and the matched normal adjacent
tissues. A similar level of overall DNA methylation in the
examined genomic regions was distributed between two types of
tissues (Figure 1B, P.0.05, Wilcoxon rank-sum test).
Identification of divergent loci of DNA methylation and
differentially expressed genes
To further study the DNA methylation status at certain genomic
regions, the genomic loci that correspond to the MluI recognition
sites were associated with genes according to their relative position
in the human genome. Up to 9034 individual genomic loci of 5656
unique genes were identified, based on the UCSC Genome
Browser. We also identified 299 individual loci that correspond to
274 genes that show a significantly different DNA methylation
level between tumors and controls (|log2Ratio|$1, FDR
P-value#0.05) (Table S1). Of the significantly different loci, 36
loci were hypermethylated and 263 loci were hypomethylated in
the tumor tissue samples compared with the matched normal
adjacent tissue samples. BSP validation confirmed 16 randomly
selected MluI genomic loci that were characterized as having
different methylation levels with an average success rate of 93.8%
(Figure 2A).
Between bladder cancer tissues and the matched normal
controls, 2975 coding genes were detected as differentially
expressed including 1560 up-regulated genes and 1415 down-
regulated genes, and 196 miRNAs were differentially expressed
including 156 up-regulated and 40 down-regulated miRNAs
(|log2Ratio|$1, FDR P-value#0.05) (Table S2 and Table S3, a
part of the mRNA and miRNA data came from our previous
studies on mRNA [21] and miRNA [22] of bladder cancer).
According to target prediction, 56 out of 196 differentially
expressed miRNAs were predicted to target 285 different mRNAs
(Table S4). As shown in Table 1, several solute carrier family
members (SLC) were consistently under-expressed in the majority
of bladder cancer tumors examined, including a facilitated glucose
transporter (SLC2A4), a mitochondrial carrier (SLC25A25), a
sodium/calcium exchanger (SLC8A1), a zinc transporter
(SLC39A14), a cationic amino acid transporter (SLC7A2), a large
neutral amino acid transporter (SLC43A1), and a monocarboxylic
acid transporter (SLC16A1). In addition, we noted that two
sodium-selective non-voltage-gated epithelial sodium channel
(ENaC) genes (SCNN1B and SCNN1G) involved in regulating
intracellular sodium homeostasis were significantly up-regulated in
our study [23,24]. A hepatocyte growth factor receptor (HGFR),
also known as MET, was also sharply up-regulated in all of the
tumors examined in our study as well. Consistent with recently
published studies, miR-182, miR-183, miR-10a, miR-203, and
miR-224 were all significantly up-regulated in the tumors, whereas
miR-1, miR-143, miR-145 were significantly down-regulated in
the tumor tissues [25]. Additionally, a typical down-regulation of
miR-133a, miR-133b and miR-125b was detected in our study
also observed formerly [26]. Remarkably, the tumor suppressors
miR-1 and miR-133a were both significantly under-expressed in
our study, resulting in the activation of the predicted target gene
transgelin 2 (TAGLN2), which has been identified as a potential
oncogene. This result is in agreement with existing knowledge
about gene expression changes in bladder cancer [16].
We performed integrated analysis of selected genes between
DNA methylation and gene expression. In total, 4772 genes with
both DNA methylation data and gene expression data were
identified. As shown in supplementary Table S5, we identified 82
simultaneously differentially methylated and expressed genes by
meeting the following conditions: |log2Ratio|$1, adjusted
P-value#0.05, for both the DNA methylation and gene expression
data. Several well-known cancer-associated genes (including
ADAMTS9, CCND1, HIC1, etc.) exhibited consistently disrupted
methylation and expression statuses in the majority of the bladder
urothelium cancer samples.
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analysis
To generate further insight view of pathway perturbation
underlying bladder cancer, we performed GO and KEGG
pathway analysis on gene sets containing differentially methylated
sites, differentially expressed genes identified from mRNA
sequencing and the target genes of deregulated miRNAs.
Among all the genes containing divergent DNA methylation
loci, the GO analysis for ‘‘biological processes’’ and ‘‘molecular
function’’ showed a significant enrichment of 19 and 13 GO terms,
respectively, using a FDR P-value cutoff of 0.05. The most
significant enriched GO terms in ‘‘biological process’’ were
‘‘neuron development’’, suggesting a critical role for differential
methylation in neurogenesis. Similarly, only the ‘‘axon guidance’’
pathway was significantly enriched (FDR P-value: 3.29E-13) via
Figure 1. Overview of DNA methylation patterns in relation to gene expression. A. Genome wide DNA methylation, mRNA, and miRNA
profiles from bladder cancer tissues and matched normal adjacent tissues. The log2-transformed average fold changes (tumor/normal) for
methylation status (red), mRNA expression level (green), and miRNA expression level (blue) from all patients were drawn across the whole genome.
The y-axis represents the log2 ratio, and the dashed lines represent the significance threshold (|log2Ratio|=1). B. Distribution of the methylation
levels in different types of genic regions between bladder cancer tissues and matched normal adjacent tissues. The box-plots for the distribution of
DNA methylation levels based on the log2-transformed tag fold change (tumor/normal) from MMSDK across all patients were drawn. Types include
CpG-rich promoters, CpG-poor promoters, exons, and introns.
doi:10.1371/journal.pone.0028223.g001
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analysis result. This result suggests an important mechanism of
epigenetic abnormality in neuron genes that play a role in bladder
cancer, as cancer-related axonogenesis and neurogenesis has been
observed in prostate cancer [27]. The remaining enriched GO
terms from the ‘‘molecular function’’ analysis were primarily
related to various transporter activities (Table S6).
For differentially expressed genes, 226 GO terms in the category
of ‘‘biological process’’ and 8 GO terms in the category of
‘‘molecular function’’ were significantly enriched at a FDR
threshold of P-value#0.05 (Table S7). From the ‘‘biological
processes’’ analysis, a prevalence of negative regulation genes was
observed in the typical down-regulated genes. Meanwhile, we also
noticed a significant frequent occurrence of genes involved in the
regulation of the cell cycle and mitosis among the up-regulated
genes. The enriched GO terms of ‘‘molecular function’’ were
primarily related to ‘‘protein kinase activity’’. KEGG pathway
analysis also revealed that several well-known cancer-associated
pathways were significantly disturbed (FDR P-value#0.05), e.g.
ECM-receptor interaction, cell cycle, p53 signaling, and Calcium
signaling pathway. Various metabolic pathways (such as those
involved in amino acid metabolism) were also observed to be
enriched in the deregulated genes identified by our study (FDR
P-value#0.05).
For the target genes of all the deregulated miRNAs, 149 GO
terms were enriched from the ‘‘biological processes’’ analysis using
the similar threshold. Generally, cellular process, biological and
metabolic process terms were found to be enriched among the
miRNA-target genes that were deregulated in our study. The
‘‘molecular function’’ analysis revealed 11 GO terms that were
significantly enriched by a FDR threshold of P-value#0.05. The
most significantly enriched GO term was ‘‘protein kinase activity’’,
Figure 2. Validation results of BSP for DNA methylation and RT-qPCR for gene expression. A. Validation results of MMSDK with BSP. To
compare the BSP-Sanger sequencing data and deep sequencing MMSDK data, the MluI loci that were determined to be differentially methylated on
average by deep sequencing were validated using BSP. The height of the columns represents the log2-transformed average fold change (tumor/
normal) in methylation level across the 9 patients. B. BSP and RT-qPCR results for four cancer-associated genes examined in 33 bladder cancer
patients. The methylation levels of promoters of four selected genes (SLIT2, HIC1, RASRAl1, KRT17) and their expression level were evaluated in a
panel of 33 samples. The height of the columns represents the log2 average fold change (tumor/normal) in methylation level (blue) or expression
level (red) across all patients. The bars represent the standard error. The number of samples (n) used in the validation assay is indicated beside each
standard error bar.
doi:10.1371/journal.pone.0028223.g002
Systematic Analysis on Methylation, mRNA and miRNA
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e28223suggesting a role in kinase activity regulation. In addition, pathway
analysis of the targets of the deregulated miRNAs also showed a
significant perturbation of cell cycle, axon guidance and MAPK
signaling pathways (adjusted P-value#0.05) (Table S8).
To further scrutinize the connection among the three categories
of -omics, the GO terms of molecular functions and biological
processes, as well as the KEGG pathways that were enriched in
more than one category were further analyzed. The GO and KO
terms enriched in more than one category are presented in Table
S9. As many as 106 enriched GO terms and KEGG pathways
were enriched in our study, the majority of which were tightly
associated with cancer. Remarkably, overlapping of significantly
enriched GO terms and KEGG pathways among three categories
of -omics was carried out subsequently, including a key neural
development pathway named ‘‘axon guidance’’. Furthermore, the
7 enriched ‘‘biological process’’ GO terms and the single
‘‘molecular function’’ GO term were primarily related to
‘‘neurogenesis’’ and ‘‘cell differentiation’’, suggesting a combined
regulation of key processes and functions by differential methyl-
ation and mRNAs and miRNAs expression regulation.
Cancer-related genes significantly deregulated in bladder
cancer
Through the GO term enrichment and KEGG pathway
analysis of selected differentially regulated genes, we observed
that certain genes were both differentially methylated and
expressed which were involved in significant perturbation
pathways, and these pathways were closely connected to various
tumorigenesis processes. For instance, SLIT2 was involved in
Axon guidance pathway, and CCND1 was involved in cell cycle
and p53 signaling pathway. Besides, we identified several
canonical cancer-associated genes that were not enriched in the
significantly disturbed pathways, such as ADAMTS9, HIC1,
RASAL1, in both the methylation statuses and expression data
(Table 2).
As DNA methylation aberration in gene promoters is reported
to influence their expression levels, those methylation sites located
in promoter regions were analyzed in details. Hypermethylated in
cancer 1 (HIC1) and slit homolog 2 (SLIT2) were identified as
having differentially up-regulated methylation status of their
promoter regions and dramatically down-regulated expression
level across all the bladder urothelial carcinoma tissue samples.
Besides, we found that RAS protein activator like 1 (RASAL1) and
keratin 17 (KRT17) were clearly hypomethylated in the promoter
region and over-expressed in the tumor samples compared to the
controls. These four genes have been identified as potential tumor
suppressor genes or oncogenes in studies of other tumor types
[28,29,30,31], but have not been implicated in bladder cancer.
To further investigate the methylation and expression alter-
ations of HIC1, SLIT2, RASAL1, and KRT17, massive bisulfite
sequencing PCR and reverse transcription qPCR were performed
in matched pairs of cancer and normal adjacent tissues from
additional ,33 bladder urothelial carcinoma patients (see methods
for details). As shown in Figure 2B, aberration of regional
promoter methylation was tightly associated with altered gene
expression in these four genes in bladder cancer. In the human
bladder urothelial carcinoma samples examined, increased HIC1
promoter methylation was detected in 100% (30/30) of the
samples and reduced expression was observed in 70.0% of the 30
tumor samples. Hypermethylation of the SLIT2 promoter was
observed in 58.6% (17/29) cases, and a significant reduction of
expression was detected at a rate of 86.2% (25/29). The decreased
methylation frequency for RASAL1 was 96.7% (29/30), and
KRT17 had a frequency of 93.9% (31/33). The corresponding
increased gene expression rates for RASAL1 and KRT17 were
63.3% (19/30) and 78.8% (26/33), respectively. In total, increased
HIC1 and SLIT2 promoter methylation and decreased expression
were observed in 70.0% and 51.7% of the tumor samples,
respectively. Meanwhile, hypomethylation of the RASAL1 and
KRT17 promoters and down-regulation of their expression were
detected at rates of 63.3% and 75.8%, respectively.
Discussion
MMSDK technology provides an efficient and cost-effective
method to analyze genome-wide DNA methylation profiles with
a relatively high sensitivity [32]. The methylation level detected
by MMSDK correlates well with those validation results of
bisulfite sequencing PCR in randomly selected MluI loci in our
study. DGE sequencing is also a useful and sensitive tool that
allows for accurate detection of a wide range of expression levels
of both mRNAs and miRNAs and thus allows for differential
expression analysis of a greater range of transcripts [33] [34].
These two technologies both couple tag generation via enzyme
digestion with next-generation deep sequencing and allow for a
Table 1. A collection of deregulated mRNAs and miRNAs detected by deep sequencing in bladder cancer.
mRNA log2Ratio(Ca/N) P-value FDR miRNA log2Ratio(Ca/N) P-value FDR
SLC2A4 22.76453644 4.97E-17 1.20E-15 miR-182 3.809715846 1.20E-11 4.64E-11
SLC8A1 22.3659033 4.00E-21 1.09E-19 miR-183 3.357301827 3.95E-12 1.67E-11
SLC25A25 22.02937463 1.82E-11 2.47E-10 miR-10a 2.638410238 0 0
SLC39A14 21.88418005 3.07E-14 6.29E-13 miR-203 2.442035548 2.04E-12 9.06E-12
SLC7A2 21.59152375 4.52E-05 0.00025956 miR-224 2.463582232 8.34E-14 4.65E-13
SLC43A1 21.56691772 0.00307625 0.011617334 miR-1 23.372834 0 0
SLC16A1 21.49139112 1.31E-08 1.30E-07 miR-143 22.3600868 0 0
SCNN1B 1.914656487 0 0 miR-145 22.23501045 0 0
SCNN1G 3.05167703 7.72E-06 5.19E-05 miR-133a 23.1155037 1.65E-38 1.35E-37
MET 4.242192911 0 0 miR-133b 23.668212 1.67E-06 4.81E-06
TAGLN2 1.11741682 3.73E-13 6.12E-12 miR-125b 22.32239525 0 0
Ca: bladder urothelial carcinoma, N: matched normal urothelium.
doi:10.1371/journal.pone.0028223.t001
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expression.
In general, a similar genome-wide methylation pattern was
found between bladder tumor and normal adjacent tissues.
Methylation levels at CpG rich and poor promoters, exons, and
introns were also similar between tumor and normal tissues,
supporting the above findings regarding the similar global
methylation patterns. In gene level, it’s well known that
inactivation of tumor-suppressor genes by site-specific hyper-
methylation contributes to the initiation and progression of human
malignancies [2,35]. Hypermethylation of HIC1 and the associ-
ated decrease in HIC1 expression is a common feature in several
cancers, such as human breast cancer [28], acute myeloid
leukemia [36], and prostate cancer [37]. In bladder cancer, a
similar study has also been carried out that quantitative
methylation-specific PCR was done at 17 gene promoters
including HIC1 in 96 malignant and 30 normal urothelial samples
[38]. found that the methylation frequencies of HIC1 promoter in
malignant and normal urothelium were 21.9% and 16.7%,
respectively. They didn’t show significant difference between
malignant and normal urothelial tissue. Here, we reported the
hypermethylation of HIC1 and the resulting decreased expression
of HIC1 mRNA in bladder cancer. The difference between our
study and Yates DR’s study might be explained by the different
resolution of technologies, as we applied high-resolution deep
sequencing technology while Yates DR’s group applied relatively
low-solution technology of quantitative MSP, or by different
sampling strategy, as we collected exactly matched pair samples of
tumor tissues and normal adjacent tissues from the same patients,
while the most of tumor tissues that Yates DR’s group collected
didn’t have matched normal tissues. HIC1 is a candidate tumor
suppressor located at 17p13.3, a region frequently found to be
hypermethylated or deleted in many types of prevalent human
tumors [39]. The entire HIC1 gene region is encompassed within
a dense CpG island that is normally unmethylated. HIC1
(hypermethylated in cancer 1) has been demonstrated to be
involved in a complex signaling pathway that impairs p53-
mediated apoptotic DNA damage response in the process of
tumorigenesis [40,41]. Epigenetic inactivation of HIC1 would
induce the deacetylation of p53, disrupting its function and
resulting in a reduced apoptotic response to DNA damage, leading
to oncogenesis and promoting tumor progression [35,41,42].
Therefore, our research indicated that promoter CpG island
hypermethylation caused HIC1 transcription inactivation and
might disrupt the complex HIC1-p53 signaling pathway in
bladder cancer.
The Slit gene family (SLIT1, SLIT2, and SLIT3) is a recently
characterized family of secreted repellents in axon guidance and
neuronal migration during the development of the central nervous
system [43,44]. A number of studies have demonstrated that
SLIT2 is epigenetically silenced by hypermethylation of the
promoter region in a broad spectrum of other tumors, such as
lung, breast, glioma, colon, and cervical cancers, leading to
inactivation of SLIT2 expression [29,45,46,47]. The conditioned
medium from SLIT2-transfected cells reduces cell growth and
induces apoptosis of colorectal carcinoma cell lines, implicating
that SLIT2 has tumor-suppressor activities [45]. Additionally,
several studies have demonstrated that SLIT2 inhibits tumor
growth and metastasis by a mechanism that involves the regulation
of tumor migration, invasion, apoptosis, and growth in breast
cancer, fibrosarcoma, and squamous Cell Carcinoma [48,49].
Hypermethylation at the promoters of genes (SLIT1, SLIT2,
SLIT3, ROBO1, and ROBO3) involved in Slit-Robo pathway
resulting in down-regulated gene expression was also indentified in
invasive cervical cancer [46]. This work identified that the tumor
suppressor gene, SLIT2, which inhibited tumor growth and
metastasis, was found inactivated by promoter hypermethylation
in bladder urothelial carcinoma as well.
Previous studies identified hypermethyled promoter regions in
some commonly methylated genes (RASSF1A, p16, MLH1,
MGMT, HOXA9) in different types of cancers. We tried to
confirm such results in bladder urothelial carcinoma as well.
Unfortunately, there were no MluI enzyme digestion sites to be
found in the promoters of these genes, thus we couldn’t
appropriately address the methylation levels of promoters in these
commonly methylated genes due to technological limitations.
However, we found that MLH1 and HOXA9, but not the others
of these commonly methylated genes, were significantly under-
expressed in bladder cancer, which were in agreement with
previous studies [10,50].
In contrast to hypermethylation, DNA hypomethylation
contributes to tumorigenesis by activating proto-oncogenes [5],
which contributes to cancer development and progression [51]. As
was mentioned in the results of massive BSP and RT-qPCR tests,
RASAL1 methylation levels were significantly down-regulated,
and the expression levels was dramatically increased in bladder
cancer cells in 66.7% and 53.3%, respectively, of the patients with
bladder cancer examined. However, conflicting results indicating
Table 2. A collection of significantly deregulated genes detected by deep sequencing in bladder cancer.
Gene Methylation Expression
log2 Ratio(Ca/N) P-value FDR log2 Ratio(Ca/N) P-Value FDR
HIC1 21.43 3.2E-13 4.94E-11 21.84 3.98E-05 0.0002313
SLIT2 21.14 9.46E-09 6.15E-07 22.90 9.68E-08 8.54E-07
RASAL1 1.11 1.99E-07 1.02E-05 3.69 5.31E-04 2.42E-03
KRT17 1.08 1.36E-04 3.32E-03 2.19 2.49E-12 3.66E-11
ADAMTS9 21.52 0 0 21.46 1.70E-03 6.85E-03
CCND1 1.51 3.53E-57 2.66E-54 1.84 0 0
ITPR3 3.71 2.75E-12 3.40E-10 1.32 1.11E-06 8.44E-06
PEX14 21.50 2.41E-06 9.30E-05 21.51 1.85E-10 2.27E-09
MEIS2 21.40 5.78E-04 1.12E-02 21.64 6.80E-08 6.08E-07
Ca: bladder urothelial carcinoma, N: matched normal urothelium.
doi:10.1371/journal.pone.0028223.t002
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multiple tumors [52] and that a reduction in RASAL1 expression
might contribute to carcinogenesis and was associated with tumor
progression [30,53] have been published. RASAL1 is a RAS-
GTPase-activating protein that switches off RAS activity by
converting the GTPase from its active, GTP-bound form to its
inactive, GDP-bound form [54]. The RAS gene family is well
known as one of the most frequently activated oncogenes in
human cancers [55]. Surprisingly, RASAL1, the RAS signal
terminator, was highly over-expressed and hypomethylation of the
promoter was also observed in the majority of the examined
bladder cancer tissues in our research. Further studies are needed
to address the mechanisms that underlie the RASAL1 over-
expression and epigenetic aberration in bladder cancer.
Keratin 17, also known as cytokeratin 17, is involved in the
formation and maintenance of various skin appendages, especially
in determining the shape and orientation of hair. The expression
of KRT17 has been found to be up-regulated in cancerous tissues
in cervical [56], tongue [57], oral [58], and esophageal squamous
cell carcinomas [59]. Increased expression of keratin 17 in
endothelial cells may contribute to angiogenesis [60] and may
promote epithelial proliferation and tumor growth [31]. Keratin
17 has also been reported as a potential diagnostic marker for oral
squamous cell carcinoma [58], and it might be linked to the
clinical progression and differentiation of cervical carcinoma
[61,62]. However, there are few reports on the epigenetic
regulation and expression of keratin 17 in bladder cancer. In this
study, we identified an increase of KRT17 expression in bladder
cancer tissues compared with their normal counterparts. We also
observed hypomethylation of the KRT17 promoter in bladder
urothelial carcinoma. KRT17 might be a putative oncogene that is
activated through hypomethylation at the promoter.
Our study also highlights the importance of investigating the
functional roles of mRNAs and miRNAs in the tumorigenesis of
bladder urothelial carcinoma. Met proto-oncogene (MET), a
hepatocyte growth factor receptor (HGFR) that has been
suggested to play an important role in the development of various
epithelial and nonepithelial tumors, was found to be significantly
over-expressed in our study of bladder cancer, consistent with
previous reports on bladder cancers [63], haematopoietic
malignancies [64], and renal cell carcinomas [65]. MET is
constitutively activated as a proto-oncogenic receptor tyrosine
kinase, which promotes invasion and migration by activating a
variety of signal transduction pathways in numerous types of
carcinomas [66]. Interestingly, the down-regulation of miR-1,
which targets MET, was observed in our study, similar to previous
studies in lung cancer and human Rhabdomyosarcoma [67,68].
MiR-1 is thought to inhibit cell proliferation and migration by
negatively regulating the c-Met signaling pathway. Therefore,
characterization of the oncogenes targeted by miRNAs would be
of great value in improving our understanding of the pathogenic
mechanisms underlying bladder cancer.
It is widely acknowledged that disrupted pathways, not just
deregulated individual genes, drive the tumorigenesis process. In
our search for functional relevance of altered methylation levels
and gene expression, we found that KEGG ‘‘axon guidance’’
pathway was significantly enriched in the differentially expressed
genes (mRNAs and miRNAs) and that there were overlaps with
the pathways enriched for relevant genes with differentially
methylated loci. Axon guidance represents a key stage during
which axons extend to their correct targets during the formation of
neuronal networks and related molecules were thought to be
widely expressed and involved in tumor development, angiogen-
esis and metastasis [69]. We also observed such overlaps for
significantly enriched GO terms, which primarily related to
‘‘neurogenesis’’ and ‘‘cell differentiation’’ (e.g. neuron differenti-
ation, neurogenesis, positive regulation of cell differentiation)
among three types of omics data. Different categories of omics
might co-regulate cellular processes simultaneously via overlap-
ping pathways, suggesting that a complex means of multilevel
regulation is involved in tumor progression.
In summary, we systematically profiled the DNA methylation
and expression patterns of both miRNAs and mRNAs on a
genome-wide scale in bladder urothelial carcinoma using deep
sequencing technology. We characterized the profiles between
methylome and transcriptome in bladder urothelial carcinoma,
identified a set of significantly enriched key pathways, and
screened four simultaneously aberrantly methylated and expressed
genes. It is noted that the number of bladder cancer patients in our
study was relatively small. This observation requires further
confirmation in a larger panel of tumors. Our results provide a
new perspective for the application of integrated analysis of multi-




The tumor tissues and matched normal adjacent tissues from
the patients with transitional cell carcinoma of the bladder in this
study were obtained from the biobank (CXC201005260001A) of
Urinogenital Cancer Genomics Consortium (UCGC) in China.
Detailed information of the 42 patients (9 for MMSDK and DGE
sequencing and 33 for validation screen) is summarized in Table
S10. Specimens were deposited in RNALater (Qiagen, Germany)
or snap-frozen in liquid nitrogen and subsequently stored at
280uC. Hematoxylin-eosin (HE)-stained sections were examined
for tumor cell percentage, and tumor tissues containing more than
85% tumor cells were selected for further study. The matched
normal adjacent tissues were defined as bladder transitional
epithelial tissues located at least 2 centimeters outside of visible
bladder cancer lesions. The collection and use of the samples were
reviewed and approved by Institutional Ethics Committees of
Peking University Shenzhen Hospital (Shenzhen, China), and
written informed consent from all the patients was obtained.
DNA and RNA extraction
Genomic DNA from bladder urothelial carcinomas and normal
adjacent tissues were prepared using DNeasy Blood & Tissue Kit
(Qiagen, Germany) according to the manufacture’s protocol, DNA
was then dissolved in DNase-free water and the concentrations
were determined before being stored at 280uC. Total RNA was
extracted from bladder cancer and normal adjacent tissues using
TRIZOL (Invitrogen, US) according to the manufacture’s
protocol and evaluated using Agilent 2100 Bioanalyzer (Agilent
Technologies, US).
MMSDK and statistical analysis
MMSDK combines the use of methylation-sensitive restriction
enzyme digestion and the second generation sequencing technique
(Illumina Genome Analyzer IIx) [32]. Briefly, 3 mg of genomic
DNA was digested with MluI (recognition sequence: ACGCGT)
(NEB, US). The MluI-digested genomic DNA was ligated to
biotinylated linkers and fragmented by NlaIII cleavage (NEB, US).
DNA fragments were captured with streptavidin-conjugated
magnetic beads and then bound to the first adapter, which
contains a MmeI restriction enzyme recognition site. Bounded
DNA was then digested with MmeI (NEB, US), which generated a
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fragments were amplified by PCR for 15 cycles using Phusion
DNA polymerase (Finnzymes, Finland) with universal primer and
index primers. Gel electrophoresis was used to isolate a 130–
150 bp gel slice, and the isolated fragment was gel-purified using
Spin-X Centrifuge Tube Filters (Corning, US). Each MMSDK
library was examined by Agilent 2100 Bioanalyzer (Agilent, US)
and real-time PCR for quality control, after which cluster
generation and a standard sequencing were performed on the
Illumina Cluster Station and Genome Analyzer IIx (Illumina, US)
following manufacturer’s protocol.
We firstly filtered the data to generate effective reads by
removing the low-quality sequences, as well as 39 adaptor
sequence, leaving tags of 17–18 nt. A virtual MluI and NlaIII
digested DNA fragment library was constructed as a reference
genome. Digital simulated analysis showed 21038 MluI recogni-
tion sites in the human genome sequence (reference build hg18). A
total of 42126 virtual fragments were obtained from simulated
digestion with MluI and NlaIII under the hypothesis that all
cytosines are unmethylated. Only 694 MluI fragments lacked an
internal NlaIII recognition site. We found 2942 genomic loci to be
located in CGIs defined by the following three criteria: GC
content $50%, ratio of the observed CpGs to the expected
CpGs.0.6, length.200 bp. The corresponding CpG Islands
annotation file was downloaded from the UCSC Table Browsers
[70]. MAQ (Mapping and Assembly with Qualities) was used to
map all tags to this library while 1 bp mismatch was allowed [71].
We extracted high-confidence mapped tags with a mapping
quality score greater than 20 to ensure unambiguous mapping and
then averaged the mapped tags across the 9 tissues at each MluI
recognition site. In our experiment, the tags represent unmethy-
lated sites. The corresponding gene annotation of those genomic
loci was simultaneously found using the UCSC Genome Browser
(http://genome.ucsc.edu/). The averaged tag numbers were
normalized (divide high-quality tags by total tags and multiplied
by one million) and were used to compared the methylation level
between tumors and normal adjacent tissues. The Poisson
distribution was used to calculate the P-value for each MluI
recognition site in the genome to detect differentially methylation
level between bladder cancer tissues and matched normal adjacent
tissues [72]. The False Discovery Rate (FDR) adjustment was
performed to judge the significance of difference in methylation
level in multiple test [73]. Genomic loci with a calculated
FDR#0.05 and a |log2Ratio|$1 were defined as being
differentially methylated.
Digital gene expression (DGE) sequencing of mRNA and
the resulting statistical analysis
To detect the expression of mRNA in the tumor tissues and
matched normal adjacent tissues, 4 mg of the total RNA isolated
from each sample was used for DGE sequencing. Briefly, after
synthesis of double-stranded cDNA using oligo(dT)18 beads
(Invitrogen, US), the cDNA was digested with NlaIII and ligated
to the first adapter (GEX adapter 1) that contained a restriction
site for MmeI. After dephosphorylation with the alkaline phospha-
tase, CIAP (Invitrogen, US), the purified MmeI-digested products
were linked to the second adaptor (GEX index adapter) containing
degenerate 2 bp 39 overhangs. The double adapter-flanked tags
from the mRNAs were then amplified by PCR using Phusion
DNA polymerase (Finnzymes, Finland) and GEX PCR primers
following the manufacturer’s protocol. The resulting ,85-bp PCR
products were ethanol precipitated and purified by gel electro-
phoresis and Spin-X filter columns (Corning, US). Finally, the
mRNA libraries were sequenced on the Illumina Cluster Station
and Genome Analyzer IIx (Illumina, US) following the manufac-
turer’s protocol.
Prior to the statistical analysis, potentially erroneous tags (single
copy tags and tags consisting of adapter sequences or containing
unknown sequences, ‘N’) were filtered out. All of the 17 bp
sequences next to the potential NlaIII restriction sites in the human
reference genome (hg18) and the CATG restriction enzyme-
digested site were extracted and concatenated to form a new
reference sequence [74]. Tags were mapped to the constructed
reference sequence using SOAP V2.0 [75] allowing no more than
1 bp mismatch. Only uniquely mapped tags were used for the
gene expression analysis. As with the MMSDK statistical analysis,
all of the mapped tags were averaged among the 9 samples.
Normalized TPM (high-quality tags per million tags) values were
used to compare the gene expression levels between tumors and
normal adjacent tissues. The expression fold change (tumor versus
normal) for each gene was calculated as the log2Ratio using the
TPM values. We subsequently performed Poisson distribution test
to determine the differentially expressed genes [72]. The resulting
P-values for all genes were corrected for multiple testing using a
FDR (false discovery rate) adjustment [73]. The mRNAs with a
calculated FDR#0.05 and a |log2Ratio|$1 were defined as
differentially expressed mRNAs.
DGE sequencing of miRNA and statistical analysis
For miRNA sequencing, 5 mg of total RNA from each sample
was ligated to both a 59 adapter and 39 adapter for reverse
transcription using Superscript II (Invitrogen, US). Subsequently,
the reverse transcripted products were amplified by PCR and
evaluated by gel electrophoresis. After obtaining a ,92 bp DNA
band from a 6% PAGE gel, the PCR products were ethanol
precipitated and purified using Spin-X filter columns (Corning,
US). Finally, miRNA libraries were performed to cluster
generation and standard cycle of sequencing on the Illumina
Cluster Station and Genome Analyzer IIx following manufactur-
er’s protocol.
Low quality reads were trimmed and the adapter sequences
were accurately clipped using a dynamic programming algorithm
prior to subsequent statistical analysis. After elimination of the
duplicate reads, the remaining reads of at least 18 nt were mapped
to a human reference genome (hg18) using SOAP V2.0. We
removed tags originating from protein-coding genes, repeat
sequences, rRNA, tRNA, snRNA, and snoRNA by mapping the
short read tags to UCSC RefGene, RepeatMasker and NCBI
Refseq, as well as our in-house ncRNA annotation datasets
compiled from the NCBI GenBank database (http://www.ncbi.
nih.gov). The same pipeline used for the DGE mRNA differential
expression analysis was also used for the miRNA expression
analysis.
To identified the target genes of deregulated miRNAs, we firstly
compared the predictions with DIANA-microT v3.0 [76],
TargetScan 5.1 [77], and PicTar [78]. These tools are
characterized by their high precision [79], and the intersecting
results of two of these three tools were obtained, To reduce the
false positive rate, we generated the union set of two experimen-
tally supported database, TarBase V5.0 [80] and miRecords V3
[81]. The intersection of the results from these two steps was
selected as representing the robust target genes and was used for
further analysis.
GO and KEGG pathway analysis
GO and KEGG pathway analysis was performed by Cytoscape
V2.7 (http://cytoscape.org/) with the ClueGo V1.3 plug-in [82].
ClueGO determines the distribution of the target gene list across
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right-side hypergeometric tests, and Benjamini-Hochberg adjust-
ment was used to multiple test correction. An adjust P-value#0.05
indicates a statistically significant deviation from the expected
distribution, and thus corresponding GO terms and pathways
were enriched in target genes. We analyzed all of the differentially
methylated loci, expressed genes, and target genes of deregulated
miRNAs using GO and KEGG pathway analysis.
Validation of DNA methylation status and the expression
of mRNAs by BSP and RT-qPCR
To validate the methylation status of genes detected as being
differentially methylated by deep sequencing, we combined BSP
and clone sequencing for 16 differentially methylated genes in
both tumor and normal adjacent tissue samples from the 9 bladder
cancer patients. In brief, 1 mg of genome DNA from each sample
was bisulfite converted according to the manufacturer’s protocol
(Qiagen, Germany). Primers for BSP were designed by MethPri-
mer (Table S11) (http://www.urogene.org/methprimer/index1.
html). The bisulfite conversion products were amplified using the
following PCR program: 94uC for 4 min, followed by 35 cycles of
94uC for 30 sec, 55uC for 30 sec, 72uC for 30 sec and then
extension at 72uC for 10 min. Then, bisulfite PCR products were
cloned into a T vector (TaKaRa, Japan) after purification, and 30
clones were selected to further Sanger sequenced for at each
validated gene.
BSP and RT-qPCR were used to further evaluate the
methylation and expression status of the HIC1, SLIT2, RASAL1,
and KRT17 genes in an additional 33 bladder cancer patients.
The BSP products were cloned into a T vector and 20 clones were
further Sanger sequenced for each gene. The BSP primers and
programs used were the same as described previously. For RT-
qPCR, 1 mg of total RNA from each sample was reverse
transcribed to cDNA using a reverse transcription kit according
to the manufacturer’s protocol (Promega, US). The reverse
transcription products were amplified using the following PCR
program: 50uC for 2 min,94uC for 2 min, followed by 40 cycles of
94uC for 30 sec, 55uC for 20 sec, and 72uC for 15 sec. All of the
primers used in the validation assays are listed in Table S11.
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